Current management and treatment strategies for breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 1, 2012, Pages 44-48

  Howard, John H ^a   Bland, Kirby I ^b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Kentucky   (United States)

Author keywords

axillary staging; breast cancer; nipple sparing mastectomy; surgical treatment

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CAUSE OF DEATH; ECHOMAMMOGRAPHY; GENETIC PREDISPOSITION; HUMAN; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT PLANNING; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; SENTINEL LYMPH NODE BIOPSY; ULTRASONOGRAPHY, MAMMARY; UNITED STATES;

EID: 84855809279     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834da4b1     Document Type: Review

References (46)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907.
2. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer, version 2.2011. 2011. http://www. nccn.org/professionals/physician-gls/pdf/breast.pdf.
3. Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009; 7:193-201.
4. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis v.1.2010. 2010 [updated 2010; cited]. http://www.nccn.org/professionals/physician-gls/PDF/breast-screening. pdf.
5. Morrow M. Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls. Surg Oncol Clin North Am 2010; 19:475-492.
6. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2011; 28:1450-1457.
7. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29:1664-1669.
8. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011; 29:2158-2164.
9. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009; 16:1597-1605.
10. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomized controlled trial. Lancet 2010; 375:563-571.
11. Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010; 14:1-182.
12. Hequet D, Bricou A, Delpech Y, Barranger E. Surgical management modifications following systematic additional shaving of cavity margins in breastconservation treatment. Ann Surg Oncol 2010; 18:114-118.
13. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009; 27:1615-1620.
14. Morrow M. Breast conservation and negative margins: how much is enough? Breast 2009; 18 (Suppl. 3):S84-S86.
15. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102:170-178.
16. Itakura K, Lessing J, Sakata T, et al. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer 2011; 11:33-38.
17. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443-448. (Pubitemid 38443647)
18. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001; 28:400-418. (Pubitemid 32762083)
19. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103:478-488.
20. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:5319-5324.
21. Kurniawan ED, Rose A, Mou A, et al. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 2010; 145:1098-1104.
22. Han JS, Molberg KH, Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 2011; 17:223-229.
23. Schneider C, Trocha S, McKinley B, et al. The use of sentinel lymph node biopsy in ductal carcinoma in situ. Am Surg 2011; 76:943-946.
24. Boneti C, Yuen J, Santiago C, et al. Oncologic safety of nipple skin-sparing or total skin-sparing mastectomies with immediate reconstruction. J Am Coll Surg 2011; 212:686-693; discussion 693-695.
25. De Alcantara Filho P, Capko D, Barry JM, et al. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the memorial sloan-kettering cancer center experience. Ann Surg Oncol 2011; 18:3117-3122.
26. Jensen JA, Orringer JS, Giuliano AE. Nipple-sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann Surg Oncol 2011; 18: 1665-1670.
27. Rusby JE, Smith BL, Gui GP. Nipple-sparing mastectomy. Br J Surg 2010; 97:305-316.
28. Weidong L, Shuling W, Xiaojing G, et al. Nipple involvement in breast cancer: retrospective analysis of 2323 consecutive mastectomy specimens. Int J Surg Pathol 2011; 19:328-334.
29. Luo D, Ha J, Latham B, et al. The accuracy of intraoperative subareolar frozen section in nipple-sparing mastectomies. Ochsner J 2010; 10:188-192.
30. Stucky CC, Gray RJ, Wasif N, et al. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol 2010; 17 (Suppl 3):330-337.
31. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Database, 1998-2007. Ann Surg Oncol 2010; 17: 2554-2562.
32. Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep 2010; 12:16-21.
33. Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 2010; 3:1026-1034.
34. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999; 353:1993-2000. (Pubitemid 29271743)
35. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967-975.
36. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010; 102:401-409.
37. Tuttle TM, Habermann EB, Virnig B. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010; 102:1371-1372; author reply 1372-1373.
38. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010; 17:2702-2709.
39. King TA, Gurevich I, Sakr R, et al. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg 2011; 254:2-7.
40. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569-575.
41. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010; 17 (Suppl 3):343-351.
42. De Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl JMed 2009; 361:653-663.
43. Brown AS, Hunt KK, Shen J, et al. Histologic changes associated with falsenegative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 2010; 116:2878-2883.
44. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010; 116:1243-1251.
45. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with earlystage invasive breast cancer. JAMA 2011; 306:385-393.
46. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364:412-421.